Roche is the recipient of the new approval, getting the go-ahead from the US regulator for its PATHWAY HER2 (4B5) test to ...

Enhertu is one of AZ's key pipeline prospects, with a peak sales estimate of $5 billion as the group chases an annual revenue target of $80 billion by 2030. In its second-quarter results update ...

FDA approves Enhertu for metastatic breast cancer with HER2-low or HER2-ultralow expression after showing significant ...

Even as Merck faces a patent cliff for Keytruda in 2028, 2025 is expected to be the drug’s peak sales year. The report also highlighted Daiichi Sankyo’s and AstraZeneca’s antibody-drug conjugate (ADC) ...

Trastuzumab deruxtecan (Enhertu; AstraZeneca, Daiichi Sankyo) is a HER2-directed antibody-drug conjugate. The agent is approved in the United States for several indications, including treatment of ...

According to GlobalData’s Pharma Intelligence Center, the drug is projected to reach $13.9bn in sales by 2030. GlobalData is the parent company of Pharmaceutical Technology. Despite Enhertu’s ...

Sales of Enhertu in the US are recognised by Daiichi Sankyo. AstraZeneca reports its share of gross profit margin from Enhertu sales in the US as Alliance Revenue in the Company’s financial statements ...

Sales of Enhertu in the US are recognised by Daiichi Sankyo. AstraZeneca reports its share of gross profit margin from Enhertu sales in the US as Alliance Revenue in the Company's financial ...

Daiichi Sankyo recognizes the U.S. sales of Enhertu while AstraZeneca records its share of gross profit margin from Enhertu sales under Alliance revenues. In the first nine months of 2024 ...

Q3 2024 Management View Revenue for Q3 FY2024 increased 16.6% year-on-year to ¥1,367.6 billion, driven by growth in oncology and international markets. Core operating profit rose 33% to ¥229 billion.

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA ...